vVardis Holding, a Switzerland-based dental medtech company pioneering non-invasive cavity treatment, has achieved unicorn status following a strategic minority investment from US-based Apollo-managed funds. The investment establishes vVardis as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVardis’ founders and co-CEOs, Drs Haley and Goly Abivardi, will retain a substantial majority shareholding in the company.
The investment will accelerate vVardis’ next phase of global growth and commercial expansion of its Curodont technology platform – the first and only clinically proven, commercially available technology that treats early tooth decay throughout the depth of the lesion without drilling or needles.
“vVardis has built a differentiated business, with Drs Haley and Goly Abivardi pioneering a new category in dental care backed by peer-reviewed clinical studies,” said Jeremy Honeth, partner and Andrea Vanni, managing director at Apollo. “Apollo Funds’ investment supports the company’s continued expansion in key markets across the US and Europe, bringing this restorative therapy to more practices and patients worldwide.”
Since the launch of Curodont Repair Fluoride Plus in the US over two years ago, it has been used to treat approximately 3 million teeth, is now present in nearly 20% of general dental practices nationwide and is one of the fastest-growing dental products in the country.
The financial terms of the transaction were not disclosed.
